Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for ...

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that biomarker data ...

A new JavaScript framework is making waves in the developer community, promising faster performance, simpler syntax, and ...

The average one-year price target for Replimune Group (NasdaqGS:REPL) has been revised to $10.84 / share. This is an increase of 48.75% from the prior estimate of $7.29 dated September 27, 2025. The ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in UnitedHealth Group Inc (Symbol: UNH), where a total volume of 92,988 contracts has ...

Replimune Group (REPL) has drawn attention after presenting updated clinical data from its IGNYTE phase 2 trial at the ESMO Congress 2025. The study combined RP1 with nivolumab in patients with acral ...

Replimune Group announced that the U.S. Food and Drug Administration has accepted the resubmission of its Biologics License Application for RP1 in combination with nivolumab, targeting advanced ...

The biotech received the good news it was hoping for from a top national regulator. This concerned RP1, its advanced melanoma drug. Well before market open, Replimune announced that the U.S. Food and ...

Replimune (REPL) stock underwent a major rally on Monday after the biotechnology company announced results from its resubmission of a Biologics License Application (BLA) for “RP1 in combination with ...

As part of ViteConf, the Vite development team announced the new Vite+ project—a command-line developer tool as a drop-in upgrade for Vite with additional features ...